#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15090	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2192	684.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1428	1428	C	902	C	839	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	147	15090	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2192	684.2	0	HET	.	.	.	C451T	.	451	451	C	695	695	C	930	C,T	617,249	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27076	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3661	737.3	0	.	n	.	0	T695C	SNP	695	695	T	1071	1071	C	810	C	754	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27076	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3661	737.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2347	2347	C	803	C	740	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27076	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3661	737.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2421	2421	A	804	A,T	754,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27076	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3661	737.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2973	2973	C	860	C	797	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	27076	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3661	737.3	0	HET	.	.	.	A1638G	.	1638	1638	A	2014	2014	A	868	A,G	462,357	.	.
folP.WHO_V_01427c	folP.WHO_V_01427c	1	1	27	1758	folP	855	855	100.0	folP.l15.c17.ctg.1	1614	108.4	1	SNP	p	R229S	1	.	.	685	687	AGC	1120	1122	AGC	190;190;190	A;G;C	177;178;177	folP.WHO_V_01427c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4720	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3390	138.9	1	SNP	p	S91F	1	.	.	271	273	TTC	595	597	TTC	152;153;157	T;T;C	141;143;143	gyrA.WHO_M_01098:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4720	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3390	138.9	1	SNP	p	G95N	0	.	.	283	285	GGC	607	609	GGC	151;149;150	G;G;C	141;138;142	gyrA.WHO_M_01098:1:1:G95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_M_01098	gyrA.WHO_M_01098	1	1	27	4720	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3390	138.9	1	SNP	p	D95G	1	.	.	283	285	GGC	607	609	GGC	151;149;150	G;G;C	141;138;142	gyrA.WHO_M_01098:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	27	1532	mtrR	633	633	100.0	mtrR.l15.c4.ctg.1	1394	109.4	1	SNP	p	G45D	0	.	.	133	135	GGC	521	523	GGC	184;182;181	G;G;C	169;166;168	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	794	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c30.ctg.1	1270	62.3	0	.	n	.	0	A197.	DEL	197	197	A	734	734	A	184	A	174	.	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5470	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2906	187.3	1	SNP	p	D86N	0	.	.	256	258	GAC	572	574	GAC	217;217;217	G;A;C	199;198;200	parC.WHO_Y_00247c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5470	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2906	187.3	1	SNP	p	R87I	0	.	.	259	261	CGT	575	577	CGT	216;216;216	C;G;T	201;198;195	parC.WHO_Y_00247c:1:1:R87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5470	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2906	187.3	1	SNP	p	R87W	0	.	.	259	261	CGT	575	577	CGT	216;216;216	C;G;T	201;198;195	parC.WHO_Y_00247c:1:1:R87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5470	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2906	187.3	1	SNP	p	S87R	1	.	.	259	261	CGT	575	577	CGT	216;216;216	C;G;T	201;198;195	parC.WHO_Y_00247c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_Y_00247c	parC.WHO_Y_00247c	1	1	27	5470	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2906	187.3	1	SNP	p	S88P	0	.	.	262	264	TCC	578	580	TCC	216;216;215	T;C;C	199;202;200	parC.WHO_Y_00247c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3546	parE	1986	1986	100.0	parE.l6.c4.ctg.1	2784	126.9	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1641	1643	GGC	156;155;155	G;G;C	148;144;145	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.34.001	penA.34.001	1	1	27	3706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2354	156.4	1	SNP	p	A311V	0	.	.	931	933	GCC	1241	1243	GCC	207;205;208	G;C;C	189;189;189	penA.34.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2354	156.4	1	SNP	p	I312M	1	.	.	934	936	ATG	1244	1246	ATG	206;210;207	A;T;G	189;191;187	penA.34.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2354	156.4	1	SNP	p	T316P	0	.	.	946	948	ACC	1256	1258	ACC	202;200;200	A;C;C	189;191;190	penA.34.001:1:1:T316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2354	156.4	1	SNP	p	V316T	1	.	.	946	948	ACC	1256	1258	ACC	202;200;200	A;C;C	189;191;190	penA.34.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2354	156.4	1	SNP	p	T483S	0	.	.	1447	1449	ACC	1757	1759	ACC	194;194;197	A,G;C,T;C	176,1;179,1;185	penA.34.001:1:1:T483S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2354	156.4	1	SNP	p	A501P	0	.	.	1501	1503	GCG	1811	1813	GCG	174;174;178	G;C;G	163;161;166	penA.34.001:1:1:A501P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2354	156.4	1	SNP	p	A501V	0	.	.	1501	1503	GCG	1811	1813	GCG	174;174;178	G;C;G	163;161;166	penA.34.001:1:1:A501V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2354	156.4	1	SNP	p	G542S	0	.	.	1624	1626	GGT	1934	1936	GGT	159;158;158	G;G;T	146;144;143	penA.34.001:1:1:G542S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2354	156.4	1	SNP	p	G545S	1	.	.	1633	1635	AGC	1943	1945	AGC	154;152;151	A;G;C	143;140;135	penA.34.001:1:1:G545S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.34.001	penA.34.001	1	1	27	3706	penA	1746	1746	100.0	penA.l15.c4.ctg.1	2354	156.4	1	SNP	p	P551S	0	.	.	1651	1653	CCG	1961	1963	CCG	134;138;135	C,G;C;G	102,6;108;109	penA.34.001:1:1:P551S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5700	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	2984	189.7	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1600	1602	CCG	201;206;211	C;C;G	185;195;196	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2184	porA	1146	1146	99.91	porA.l15.c17.ctg.1	1746	123.4	0	.	p	.	0	M83fs	FSHIFT	247	247	A	644	644	C	134	C	125	.	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2922	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1459	198.1	1	SNP	p	G120K	1	.	.	358	360	AAG	604	606	AAG	223;224;225	A;A;G,T	217;217;218,1	porB1b.WHO_Y_02277c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2922	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1459	198.1	1	SNP	p	A121N	1	.	.	361	363	AAC	607	609	AAC	223;225;227	A;A;C	217;217;222	porB1b.WHO_Y_02277c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_Y_02277c	porB1b.WHO_Y_02277c	1	1	27	2922	porB1b	1038	1038	100.0	porB1b.l6.c4.ctg.1	1459	198.1	1	SNP	p	N121D	0	.	.	361	363	AAC	607	609	AAC	223;225;227	A;A;C	217;217;222	porB1b.WHO_Y_02277c:1:1:N121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11160	rpoB	4179	4179	99.98	rpoB.l15.c30.ctg.1	4828	230.5	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1298	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1037	124.3	1	SNP	p	V57M	1	.	.	169	171	ATG	514	516	ATG	257;256;257	A;T;G	244;243;244	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
